OCA
Octagon Capital Advisors Portfolio holdings
AUM
$641M
1-Year Est. Return
327.85%
1 Year Est. Return
+327.85%
AUM
$641M
AUM Growth
+$185M
(+41%)
Holding
33
Top Buys
| 1 | +$9.58M | |
| 2 | +$9.18M | |
| 3 | +$5.32M | |
| 4 |
ABVX
Abivax
ABVX
|
+$4.92M |
| 5 |
PepGen
PEPG
|
+$3.23M |
Top Sells
| 1 | +$31.9M | |
| 2 | +$23.6M | |
| 3 | +$19.4M | |
| 4 |
Nuvation Bio
NUVB
|
+$18.7M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$14.5M |
Sector Composition
| 1 | Healthcare | 99.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$9.54B
| $112M | 17.05% |
1,325,000
+58,000
|
|
||
2
Dianthus Therapeutics
DNTH
$1.84B
| $95.1M | 14.41% |
2,416,667
+75,000
|
|
||
3
Gossamer Bio
GOSS
$731M
| $44.8M | 6.8% |
17,050,000
-1,300,000
|
|
||
4
Cogent Biosciences
COGT
$6.01B
| $41.3M | 6.26% |
2,874,111
+111,111
|
|
||
5
ArriVent BioPharma
AVBP
$930M
| $36.4M | 5.51% |
1,971,054
+25,000
|
|
||
6
Ocular Therapeutix
OCUL
$2.51B
| $30.7M | 4.65% |
2,624,000
+199,000
|
|
||
7
Taysha Gene Therapies
TSHA
$1.24B
| $29.7M | 4.49% |
9,067,500
-3,525,000
|
|
||
8
Merus
MRUS
$7.28B
| $29M | 4.4% |
308,000
-81,000
|
|
||
9
Trevi Therapeutics
TRVI
$1.65B
| $25.8M | 3.9% |
2,815,000
-857,000
|
|
||
10
MindMed
MNMD
$1.2B
| $25.1M | 3.81% |
2,130,000
|
|
||
11
Apellis Pharmaceuticals
APLS
$2.68B
| $20.4M | 3.1% |
903,500
|
|
||
12
Kymera Therapeutics
KYMR
$4.83B
| $20.4M | 3.09% |
360,000
+94,000
|
|
||
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$4.21B
| $20.1M | 3.05% |
830,000
-200,000
|
|
||
14
Pharvaris
PHVS
$1.75B
| $18M | 2.73% |
722,595
+50,000
|
|
||
15
KalVista Pharmaceuticals
KALV
$681M
| $15.5M | 2.35% |
1,273,333
|
|
||
16
Corbus Pharmaceuticals
CRBP
$193M
| $14.1M | 2.14% |
1,115,000
|
|
||
|
BBOT
17
BridgeBio Oncology
BBOT
$931M
| $12.1M | 1.83% |
1,043,110
+793,110
|
|
||
|
DBVT
18
DBV Technologies
DBVT
$507M
| $10.2M | 1.54% |
1,018,021
|
|
||
|
19
Nuvation Bio
NUVB
$2.7B
| $9.74M | 1.48% |
2,633,334
-5,058,000
|
|
||
20
Cidara Therapeutics
CDTX
$6.91B
| $9.58M | 1.45% |
+100,000
|
|
||
|
MAZE
21
Maze Therapeutics
MAZE
$1.8B
| $4.61M | 0.7% |
177,667
|
|
||
22
Neurogene
NGNE
$310M
| $4.37M | 0.66% |
252,000
-51,000
|
|
||
23
Unicycive Therapeutics
UNCY
$133M
| $4.36M | 0.66% |
1,000,000
|
|
||
|
24
PepGen
PEPG
$409M
| $3.23M | 0.49% |
+700,000
|
|
||
25
Structure Therapeutics
GPCR
$2.14B
| $3.22M | 0.49% |
+115,000
|
|